Description
On November 28, 2018, the Food and Drug Administration approved gilteritinib for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Gilteritinib was granted orphan drug status by the U.S. FDA, the European Commission (EC) and the Japan Ministry of Health, Labor and Welfare, for some AML patients. Gilteritinib was approved for medical use in Australia in March 2020.
What is the process for submitting a delivery request?
For more information on products or how to order you can submit an online request or reach us on the given contact details, we will get back to you shortly.
We distribute a diverse range of pharmaceutical drugs, catering to the entirety of the pharmaceutical trade, which includes wholesale, tender supplies, orphan drugs, named patient access, biologics, biosimilars, and vaccines.
References:
FAQs
Is branded-generic versions for Xospata (gilteritinib) Tablets is available in India?
The branded-generic versions for Xospata (gilteritinib) Tablets is available in India through Alleviare. For information on quality, pricing or bulk orders of branded-generic versions manufactured by the pharmaceutical company in India., please send us a message.
What is the price of Xospata (gilteritinib) Tablets in India?
Xospata (gilteritinib) Tablets price in India is reasonable and can vary. To procure Xospata (gilteritinib) Tablets legally, you can call us at 9643240915 (Mr. Yashpal Singh) 9289711087 (Ms. Sana Sadyar), Or Write us at alleviare.exports@gmail.com or sana.sadyar@alleviareindia.com.
Do Alleviare Export Xospata (gilteritinib) Tablets?
Yes Alleviare export Xospata (gilteritinib) Tablets. Alleviare is one of the worldwide supplier of off patented drugs – Xospata (gilteritinib) Tablets. It has wide range of pharma product range, about 15,000 different generic brands across 40 plus therapeutic categories. Alleviare can assist in the delivery of Xospata (gilteritinib) Tablets; the doctor-prescribed medication to the Europe (such as UK, Hungary, Ireland, Latvia, Slovakia, Czech Republic, Belgium, Lithania, Greece, Spain, Maldova, Germany, Sweden, Italy, Bulgaria, Romania, Montenegro, Russia), Canada, UAE, Saudi Arabia, Kuwait, Qatar, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, Australia, New Zealand, Philippines, the USA, Thailand, China, South Africa, Kazakhstan, Uzbekistan, Hong Kong, Zimbabwe, Zambia, Pakistan, Sri Lanka, Turkey, Afghanistan, Malaysia, Singapore, Japan, Nepal, and many other countries.
What steps should be followed to purchase Xospata (gilteritinib) Tablets from ALS?
If you are looking generic brands for Xospata (gilteritinib) Tablets in India. Please call us at +91 9643240915 (Mr. Yashpal Singh) +91 9289711087 (Ms. Sana Sadyar), Or Write us at alleviare.exports@gmail.com or sana.sadyar@alleviareindia.com. Our support team will be happy to assist you and answer any questions you may have.
Why do generic medicines often cost less than the brand-name medicines?
Generic drugs are approved only after a rigorous review by FDA and after a set period of time that the brand product has been on the market exclusively. This is because new drugs, like other new products, are usually protected by patents that prohibit others from making and selling copies of the same drug.
Generic drugs tend to cost less than their brand-name counterparts because generic drug applicants do not have to repeat animal and clinical (human) studies that were required of the brand-name medicines to demonstrate safety and effectiveness. This abbreviated pathway is why the application is called an “abbreviated new drug application.”
Reference :
www.fda.gov
Where can I find more information about generic medicines?
Contact your doctor, pharmacist, or other health care provider for information on generic medicines. For more information, you can also:
Shipped Brand Names by Country
(AE) United Arab Emirates: gilteritinib Tablets; (AR) Argentina: gilteritinib Tablets; (AT) Austria: gilteritinib Tablets; (AU) Australia: gilteritinib Tablets; (BD) Bangladesh: gilteritinib Tablets; (BE) Belgium: gilteritinib Tablets; (BG) Bulgaria: gilteritinib Tablets; (BR) Brazil: gilteritinib Tablets; (CH) Switzerland: gilteritinib Tablets; (CN) China: gilteritinib Tablets; (CO) Colombia: gilteritinib Tablets; (CZ) Czech Republic: gilteritinib Tablets; (DE) Germany: gilteritinib Tablets; (EC) Ecuador: gilteritinib Tablets; (EE) Estonia: gilteritinib Tablets; (EG) Egypt: gilteritinib Tablets; (ES) Spain: gilteritinib Tablets; (FI) Finland: gilteritinib Tablets; (FR) France: gilteritinib Tablets; (GB) United Kingdom: gilteritinib Tablets; (GR) Greece: gilteritinib Tablets; (HK) Hong Kong: gilteritinib Tablets; (HR) Croatia: gilteritinib Tablets; (HU) Hungary: gilteritinib Tablets; (ID) Indonesia: gilteritinib Tablets; (IE) Ireland: gilteritinib Tablets; (IN) India: gilteritinib Tablets; (IT) Italy: gilteritinib Tablets; (JO) Jordan: gilteritinib Tablets; (JP) Japan: gilteritinib Tablets; (KR) Korea, Republic of: gilteritinib Tablets; (KW) Kuwait: gilteritinib Tablets; (LB) Lebanon: gilteritinib Tablets; (LT) Lithuania: gilteritinib Tablets; (LV) Latvia: gilteritinib Tablets; (MX) Mexico: gilteritinib Tablets; (MY) Malaysia: gilteritinib Tablets; (NL) Netherlands: gilteritinib Tablets; (NO) Norway: gilteritinib Tablets; (PE) Peru: gilteritinib Tablets; (PH) Philippines: gilteritinib Tablets; (PL) Poland: gilteritinib Tablets; (PY) Paraguay: gilteritinib Tablets; (QA) Qatar: gilteritinib Tablets; (RO) Romania: gilteritinib Tablets; (RU) Russian Federation: gilteritinib Tablets; (SA) Saudi Arabia: gilteritinib Tablets; (SE) Sweden: gilteritinib Tablets; (SG) Singapore: gilteritinib Tablets; (SI) Slovenia: gilteritinib Tablets; (SK) Slovakia: gilteritinib Tablets; (TH) Thailand: gilteritinib Tablets; (TN) Tunisia: gilteritinib Tablets; (TR) Turkey: gilteritinib Tablets; (TW) Taiwan: gilteritinib Tablets; (UA) Ukraine: gilteritinib Tablets; (UY) Uruguay: gilteritinib Tablets; (ZA) South Africa: gilteritinib Tablets